Published in Hepatology on February 01, 2010
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther (2012) 3.25
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology (2013) 2.03
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol (2014) 1.10
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci (2014) 1.07
Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis (2012) 1.05
Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol (2014) 1.04
Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology (2013) 0.99
Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol (2011) 0.95
Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol (2014) 0.95
Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One (2013) 0.92
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs (2015) 0.91
Moro orange juice prevents fatty liver in mice. World J Gastroenterol (2012) 0.88
Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y) (2012) 0.87
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol (2014) 0.85
Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? J Gastroenterol (2012) 0.84
Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. World J Gastroenterol (2013) 0.84
Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver (2017) 0.82
A Systems Biology Approach to Deciphering the Etiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells. Front Physiol (2012) 0.82
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol (2012) 0.82
Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci (2016) 0.80
A case of cryoglobulinemia associated with nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y) (2012) 0.80
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci (2012) 0.79
Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. Int J Mol Sci (2015) 0.79
Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. Exp Mol Med (2014) 0.79
Molecular Pathogenesis of NASH. Int J Mol Sci (2016) 0.78
The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One (2014) 0.78
Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford) (2011) 0.78
Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci (2016) 0.77
Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.77
Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep (2014) 0.77
Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol (2015) 0.77
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int (2015) 0.76
The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract (2016) 0.76
Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther (2011) 0.76
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology (2017) 0.75
Genetic Variants in the SAMM50 Gene Create Susceptibility to Nonalcoholic Fatty Liver Disease in a Chinese Han Population. Hepat Mon (2015) 0.75
Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology (2016) 0.75
Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of Kruppel-like-factor 10 in mice. J Transl Med (2014) 0.75
IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci Rep (2016) 0.75
Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population. PLoS One (2017) 0.75
Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. AIDS (2017) 0.75
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism (2016) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (2010) 3.03
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol (2009) 1.65
Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol (2008) 1.49
Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res (2005) 1.02
Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol (2002) 1.02
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol (2005) 2.46
Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology (2006) 2.25
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology (2006) 2.06
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
The natural history of small-duct primary sclerosing cholangitis. Gastroenterology (2008) 1.92
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg (2011) 1.78
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol (2003) 1.48
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43
Recurrent idiopathic hepatitis: a new entity? J Clin Gastroenterol (2003) 1.38
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol (2010) 1.37
Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol (2002) 1.33
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int (2005) 1.27
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res (2011) 1.15
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology (2011) 1.12
Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology (2005) 1.12
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 1.07
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci (2014) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis (2012) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol (2003) 1.00
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 0.99
Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int (2006) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99
Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis (2007) 0.98
Hepatitis C and steatosis. Arch Med Res (2007) 0.98
Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol (2007) 0.97
Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol (2007) 0.94
Non-alcoholic fatty liver disease. Scand J Gastroenterol (2007) 0.94
Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2005) 0.93
Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol (2011) 0.89
Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.89
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res (2012) 0.88
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res (2013) 0.86
The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int (2006) 0.84
Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother (2013) 0.83
Association of primary biliary cirrhosis and rheumatoid arthritis. J Clin Rheumatol (2003) 0.83
Cholangiocarcinoma in pregnancy: a case report. J Obstet Gynaecol Res (2008) 0.83
Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol (2003) 0.83
Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int (2005) 0.83
Clinical trials: Trial design in NASH--realities and challenges. Nat Rev Gastroenterol Hepatol (2011) 0.83
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol (2006) 0.81
Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol (2005) 0.81
A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int (2010) 0.80
The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci (2012) 0.79
Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology (2008) 0.79
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol (2002) 0.79
Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol (2003) 0.77
Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int (2007) 0.77
Right upper-quadrant pain in a patient with drug abuse, secondary syphilis and occult hepatitis B virus. Med Princ Pract (2014) 0.76
Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers? Clin Gastroenterol Hepatol (2004) 0.76
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci (2009) 0.76
Nonalcoholic fatty liver disease: what are the odds your patient will get a transplant? Clin Gastroenterol Hepatol (2011) 0.75
The bulge, booze, and the liver. Clin Gastroenterol Hepatol (2005) 0.75
Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis. Am J Gastroenterol (2004) 0.75
Cryoglobulins in nonalcoholic Fatty-liver disease: what is the association? Gastroenterol Hepatol (N Y) (2012) 0.75
Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. Dev Immunol (2002) 0.75
Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. Clin Chem Lab Med (2015) 0.75
Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply. Arch Surg (2012) 0.75
[Auto-antibodies in liver disease]. Rev Gastroenterol Mex (2007) 0.75
Open-label pilot study of tetracycline in the treatment of primary biliary cirrhosis. Am J Gastroenterol (2004) 0.75